Charles W. Olanow
#133,038
Most Influential Person Now
Charles W. Olanow's AcademicInfluence.com Rankings
Charles W. Olanowphilosophy Degrees
Philosophy
#6570
World Rank
#9626
Historical Rank
Logic
#3717
World Rank
#4915
Historical Rank
Download Badge
Philosophy
Why Is Charles W. Olanow Influential?
(Suggest an Edit or Addition)Charles W. Olanow's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- MDS clinical diagnostic criteria for Parkinson's disease (2015) (3560)
- Levodopa and the progression of Parkinson's disease. (2004) (1676)
- Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease (2008) (1513)
- A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease (2003) (1457)
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
- Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (2007) (918)
- International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study (2006) (912)
- MDS research criteria for prodromal Parkinson's disease (2015) (897)
- Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. (2013) (866)
- The scientific and clinical basis for the treatment of Parkinson disease (2009) (2009) (814)
- Pathophysiology of the basal ganglia in Parkinson's disease (2000) (800)
- Etiology and pathogenesis of Parkinson's disease. (1999) (661)
- Evidence of neuronal oxidative damage in Alzheimer's disease. (1996) (645)
- An algorithm (decision tree) for the management of Parkinson’s disease (2001): (1998) (591)
- Protein Nitration in Parkinson's Disease (1998) (560)
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease (2004) (543)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease. (2009) (526)
- Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial (2008) (526)
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (2014) (524)
- Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients (2007) (511)
- Fetal nigral transplantation as a therapy for Parkinson's disease (1996) (503)
- High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor (1997) (493)
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial (2010) (490)
- Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications (2006) (486)
- Levodopa motor complications in Parkinson's disease (2000) (483)
- Manganese‐Induced Parkinsonism and Parkinson's Disease (2004) (426)
- Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection (1998) (415)
- Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease (1995) (396)
- Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions (2009) (378)
- Levodopa in the treatment of Parkinson's disease: Current controversies (2004) (370)
- The effect of deprenyl and levodopa on the progression of Parkinson's disease (1995) (341)
- An algorithm (decision tree) for the management of Parkinson's disease (1998) (336)
- Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder? (2013) (336)
- Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations (2015) (331)
- The basal ganglia in Parkinson's disease: Current concepts and unexplained observations (2008) (326)
- Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures (2002) (321)
- Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies (1996) (313)
- Lewy-body formation is an aggresome-related process: a hypothesis (2004) (300)
- Aggresome‐related biogenesis of Lewy bodies (2002) (281)
- Transplanted dopaminergic neurons develop PD pathologic changes: A second case report (2008) (272)
- The Neuropathology of Manganese-Induced Parkinsonism (2007) (269)
- Proteasome inhibition causes nigral degeneration with inclusion bodies in rats (2002) (266)
- Apoptosis in neurodegenerative diseases: the role of mitochondria. (1999) (261)
- Manganese intoxication in the rhesus monkey (1996) (261)
- Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants (2007) (260)
- Is Parkinson's disease a prion disorder? (2009) (252)
- Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial (2002) (251)
- Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial (2007) (250)
- Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. (2005) (235)
- A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease (1998) (219)
- Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease (2003) (209)
- Ubiquitin–proteasome system and Parkinson's disease (2006) (209)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (2011) (207)
- Subthalamic deep brain stimulation and impulse control in Parkinson’s disease (2009) (179)
- The scientific basis for the current treatment of Parkinson's disease. (2004) (172)
- Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study) (2004) (172)
- Sleepiness in Parkinson's disease: A controlled study (2003) (170)
- Why have we failed to achieve neuroprotection in Parkinson's disease? (2008) (167)
- Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains (2011) (159)
- Dopamine receptors: from structure to behavior (2000) (159)
- A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics (2008) (158)
- Waking up to sleep episodes in Parkinson's Disease (2000) (157)
- Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease (2006) (157)
- Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. (2002) (155)
- Brainstem pathology in DYT1 primary torsion dystonia (2004) (153)
- TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial (2006) (151)
- Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities (2013) (144)
- Tolcapone and Hepatotoxic Effects (2000) (140)
- Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick’s disease (1996) (132)
- Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease (2006) (129)
- Therapeutic prospects for Parkinson disease (2013) (121)
- Development of dopaminergic neurons in the human substantia nigra (1991) (119)
- The role of deep brain stimulation as a surgical treatment for Parkinson's disease. (2000) (118)
- TorsinA accumulation in Lewy bodies in sporadic Parkinson’s disease (2000) (110)
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial (2014) (109)
- Blood Manganese Correlates with Brain Magnetic Resonance Imaging Changes in Patients with Liver Disease (1996) (107)
- Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. (1997) (106)
- The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts. (1995) (105)
- Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients (2004) (104)
- l‐Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor‐Mediated Toxicity In Vitro (1997) (104)
- Neuroprotection in Parkinson's disease: Clinical trials (2003) (104)
- Movement disorders and AIDS: a review. (2004) (102)
- Treatment of levodopa‐induced motor complications (2008) (101)
- Modeling Parkinson's disease (2009) (101)
- Early Single Cell Bifurcation of Pro- and Antiapoptotic States during Oxidative Stress* (2004) (98)
- Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study. (2004) (96)
- p53 Mediates Nontranscriptional Cell Death in Dopaminergic Cells in Response to Proteasome Inhibition* (2006) (94)
- Effect of selegiline on mortality in patients with Parkinson's disease (1998) (93)
- Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. (2003) (87)
- Levodopa: Effect on cell death and the natural history of Parkinson's disease (2015) (86)
- Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video‐based analysis (2009) (86)
- Tolcapone: An Efficacy and Safety Review (2007) (2007) (85)
- Differential Modulation of Akt/Glycogen Synthase Kinase-3β Pathway Regulates Apoptotic and Cytoprotective Signaling Responses* (2008) (82)
- Dopaminergic transplantation for parkinson's disease: Current status and future prospects (2009) (82)
- Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. (1998) (82)
- Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. (2003) (81)
- The causes of parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality (1998) (79)
- Continuous dopaminergic stimulation in early and advanced Parkinson’s disease (2004) (77)
- Disease modification and biomarker development in Parkinson disease (2020) (74)
- The new definition and diagnostic criteria of Parkinson's disease (2016) (74)
- Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease (2012) (73)
- The significance of defining preclinical or prodromal Parkinson's disease (2012) (72)
- Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient (2016) (70)
- Rationale for considering that propargylamines might be neuroprotective in Parkinson’s disease (2006) (70)
- Magnetic Resonance Imaging of Corticobasal Degeneration (1996) (68)
- Levodopa: A new look at an old friend (2018) (68)
- COMT inhibitors in Parkinson’s disease (2004) (66)
- Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy (2005) (66)
- Drug selection and timing of initiation of treatment in early Parkinson's disease (2008) (65)
- Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies (2015) (65)
- Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease. (2019) (64)
- Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions (2008) (63)
- A Rationale for Dopamine Agonists as Primary Therapy for Parkinson’s Disease (1992) (61)
- Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress (2004) (58)
- Trophic factors for Parkinson's disease: To live or let die (2015) (57)
- Can we achieve neuroprotection with currently available anti-parkinsonian interventions? (2009) (56)
- Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study (2019) (55)
- Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain (2001) (54)
- Glial Cells Mediate Toxicity in Glutathione‐Depleted Mesencephalic Cultures (1999) (51)
- Parkinson's disease, proteins, and prions: Milestones (2011) (50)
- Clinical usefulness of the Parkinson's disease sleep scale. (2005) (50)
- Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease (2013) (48)
- Attempts to obtain neuroprotection in Parkinson's disease (1997) (47)
- A rationale for monoamine oxidase inhibition as neuroprotective therapy for parkinson's disease (1993) (47)
- Perampanel in Parkinson Disease Fluctuations: A Double-Blind Randomized Trial With Placebo and Entacapone (2012) (45)
- Selegiline and mortality in Parkinson's disease (1996) (45)
- Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction (2009) (45)
- Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson’s disease (2020) (45)
- “Psychogenic Movement Disorders”: They Are What They Are (2014) (44)
- Neuropathology of fetal nigral grafts in patients with Parkinson's disease. (1998) (43)
- Neural transplantation as a therapy for Parkinson's disease. (1997) (43)
- Parkinson's Disease: Non-Motor and Non-Dopaminergic Features (2011) (42)
- The role of dopamine agonists in the treatment of early Parkinson’s disease (2002) (41)
- Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD) (2004) (39)
- Do prions cause Parkinson disease?: The evidence accumulates (2014) (37)
- Long‐term effects of rasagiline and the natural history of treated Parkinson's disease (2016) (37)
- Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. (2000) (37)
- Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy. (2007) (34)
- Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait. (2010) (34)
- Selegiline: Current perspectives on issues related to neuroprotection and mortality (1996) (33)
- Huntington's disease: Current and future therapeutic prospects (2018) (33)
- Peripheral alpha‐synuclein and Parkinson's disease (2014) (32)
- Regulatable promoters and gene therapy for Parkinson's disease: Is the only thing to fear, fear itself? (2008) (32)
- Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities (2020) (31)
- The Influence of Donor Age on the Survival of Solid and Suspension Intraparenchymal Human Embryonic Nigral Grafts (1995) (29)
- Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. (2003) (29)
- Prevalence of movement disorders in an elderly nursing home population. (2008) (28)
- Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. (1996) (27)
- GPi pallidotomy—have we made a dent in Parkinson's disease? (1996) (26)
- Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets (2010) (24)
- A randomized trial of a low‐dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease (2017) (24)
- Surgical therapies for Parkinson's disease. A physician's perspective. (2001) (23)
- Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanisms of protection (2002) (22)
- Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study (2020) (21)
- Surgical therapy for Parkinson's disease. (2002) (20)
- Fetal Grafting for Parkinson's Disease: Expression of Immune Markers in Two Patients with Functional Fetal Nigral Implants (1997) (20)
- Dietary vitamin E and Parkinson's disease: something to chew on (2003) (19)
- A phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (Syn-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopa (2013) (17)
- Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less (2019) (17)
- The delayed-start study in Parkinson disease (2010) (16)
- Basal ganglia, Parkinson's disease and levedopa therapy (2000) (16)
- Differential role of dopamine in emotional attention and memory: Evidence from Parkinson's disease (2011) (16)
- Infectious issues in human fetal neural transplantation. (1997) (15)
- Milestones in movement disorders clinical trials: Advances and landmark studies (2011) (15)
- Once‐Weekly Subcutaneous Delivery of Polymer‐Linked Rotigotine (SER‐214) Provides Continuous Plasma Levels in Parkinson's Disease Patients (2020) (14)
- Present and future directions in the management of motor complications in patients with advanced PD (2003) (13)
- Parkinson disease: Gene therapy for Parkinson disease—a hope, or a dream? (2014) (12)
- Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity (2021) (12)
- Neuroprotection in Parkinson's disease: Clinical trials. Discussion (2003) (12)
- Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study (2021) (12)
- Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study (2020) (12)
- Safinamide – A New Therapeutic Option to Address Motor Symptoms and Motor Complications in Mid- to Late-stage Parkinson’s Disease (2016) (11)
- On‐Demand Therapy for OFF Episodes in Parkinson's Disease (2021) (10)
- Current status of selegiline as a neuroprotective agent in Parkinson's disease. (1998) (9)
- Manganese-Induced Neurotoxicity (1994) (9)
- Targeting α -synuclein for treating Parkinson’s disease: mechanistic and therapeutic considerations (2017) (9)
- A Model-Based Approach for Assessing Parkinsonian Gait and Effects of Levodopa and Deep Brain Stimulation (2006) (9)
- A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic (2020) (9)
- Advances in clinical trials for movement disorders (2015) (9)
- Treatment with fetal allografts (1997) (8)
- A colonic biomarker of Parkinson's disease? (2012) (7)
- The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease (2011) (7)
- The Vatican Meeting on Neuroprotection for Parkinson's Disease (2013) (7)
- Neuroprotective agents in Parkinson's disease: clinical evidence and caveats. (2004) (6)
- Stem cells for Parkinson's disease: Advancing science but protecting patients (2012) (6)
- A rational approach to the treatment of early Parkinson's disease. (1999) (5)
- Intranigral iron infusion in the rat (1997) (5)
- Initiating levodopa therapy for Parkinson's disease (2014) (5)
- Cortical Mapping of Pathological Tau Proteins in Several Neurodegenerative Disorders (1997) (5)
- Fetal Nigral Transplantation in Parkinson’s Disease (1996) (5)
- Comprar Parkinson's disease. Non-motor and non-dopaminergic features | C. Olanow | 9781405191852 | Wiley (2011) (5)
- Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease. (2021) (4)
- A Phase 3 Study of Tozadenant (TOZ-PD) as a Maintenance Therapy for Patients With Parkinson’s Disease Experiencing Motor Fluctuations: Characterization of Study Population (P2.045) (2018) (4)
- Progressive dementia and gait disorder in a 78 year old woman (2000) (4)
- Fetal Nigral Transplantation in Parkinson's Disease: The USF Pilot Program (12- to 24-Month Evaluation) (1998) (4)
- Pharmacokinetics of Opicapone and Effect on Comt and Levodopa Pharmacokinetics in Patients with Parkinson's Disease (2019) (4)
- The baton is passed (2010) (2)
- The iNDiGO study: A multicenter, randomized, double-blind, placebo-controlled clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in fluctuating PD (P2.044) (2018) (2)
- Oxidative Stress with Emphasis on the Role of LAMMA in Parkinson’s Disease (1997) (2)
- Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients (S26.003) (2018) (2)
- Prospects for Neuroprotective Therapies that can Modulate Non‐Dopaminergic Features in Parkinson's Disease (2011) (1)
- Efficacy of ND0612 for nocturnal problems and early morning OFF: A blinded rater study of 2 dosing regimens (P2.8-052) (2019) (1)
- BouNDless: An active-controlled, randomised, double-blind, double-dummy trial of continuous subcutaneous infusion of levodopa/carbidopa with ND0612 in patients with Parkinson's disease (2020) (1)
- Adverse event reporting in clinical trials in Parkinson's Disease: Time for change (2018) (1)
- Translating scientific advances into disease-modifying therapies for Parkinson's Disease (2017) (1)
- Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research Awardees (2014) (1)
- P2.113 Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD) (2009) (1)
- Preserved Emotional Modulation of Motor Response Time Despite Psychomotor Slowing in Young-Old Adults (2011) (1)
- The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration (2008) (1)
- International validation study of the first comprehensive unified Nonmotor Symptoms Scale (NMSS) for Parkinson's disease (PD) (2006) (1)
- Complications of levodopa therapy in Parkinson’s disease (2019) (1)
- Subthalamic deep brain stimulation and obsessive-compulsive symptoms in Parkinson's disease (2008) (1)
- Double-Blind, Double-Dummy, Randomized Study of Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease (1)
- Erratum: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study (2010) (1)
- Reply (2004) (0)
- A 61-Year-Old Man With Parkinson's Disease-Reply (1996) (0)
- [Medical therapy for Parkinson's disease--the current state of the art]. (2012) (0)
- Chapter 1 The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease (2011) (0)
- Abnormality in Parkinsonian Gait Frequency-Velocity Mismatch: A Fundamental (2015) (0)
- Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates (2005) (0)
- Infectious disease issues in fetal tissue transplantation for Parkinson's disease (1993) (0)
- Reply: Levodopa in the treatment of Parkinson's disease: Current controversies (2005) (0)
- 2.449 Neuroprotection by rotigotine requires activation of dopamine D2 receptor and Akt/glycogen synthase kinase-3beta (2007) (0)
- Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa (2023) (0)
- Selegiline (1996) (0)
- Animal Models of Parkinson's Disease: The Non‐Motor and Non‐Dopaminergic Features (2011) (0)
- Article Commentary: Infectious Issues in Human Fetal Neural Transplantation (1997) (0)
- Reply (2011) (0)
- From OFF to ON—Treating OFF Episodes in Parkinson’s Disease (2020) (0)
- Eldad Melamed 1942‐2015: Ave atque—A memorial (2016) (0)
- The state of the journal—2013 (2013) (0)
- Emotional processing in Parkinson's disease: a reaction time study (2007) (0)
- The use of cosmetic surgical placebo controlled trials (1996) (0)
- 2.252 Lisuride long term s.c. infusion in advanced Parkinson's disease patients unresponsive to oral treatments (2007) (0)
- 3.226 The frequency and magnitude of impulse control deficits in Parkinson's disease patients with deep brain stimulation of the subthalamic nucleus (2007) (0)
- A 61-year-old man with Parkinson's disease. (1996) (0)
- High Frequency Stimulation of the Subthalamic Nucleus as a Treatment for Parkinson's Disease: A 12 Month Follow-up Study (1999) (0)
- Risk of dyskinesia in Parkinson's disease patients who already have developed wearing-off: A secondary analysis of STRIDE-PD study (2013) (0)
- Surgical treatment of Parkinson's disease (1992) (0)
- Cell-Based and Gene-Based Therapy for Parkinson's Disease (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Charles W. Olanow?
Charles W. Olanow is affiliated with the following schools:
